Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EyePoint's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EyePoint's regulatory disclosures and financial reporting.
EyePoint, Inc. (EYPT) reported internal equity transfers by Chief Financial Officer George Elston on August 20, 2026. A total of 5,000 shares of common stock were shifted from an irrevocable family trust into Elston’s direct ownership, while 64,953 shares were transferred as a bona fide gift from his direct holdings into a grantor-retained annuity trust (GRAT) he serves as grantor, trustee and beneficiary. The family trust continues to hold 25,000 shares for the benefit of his children, and Elston disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. (EYPT) director Karen L. Zaderej reported an open-market or private purchase of 10,600 shares of Common Stock on 2026-08-18 at $4.93 per share. Following this transaction, she directly owns 49,100 shares of EyePoint, Inc. common stock. The Rule 10b5-1 trading plan checkbox was not marked, indicating the trade was not reported as made under such a plan.
EyePoint, Inc. reported topline Phase 3 results from LUGANO, its first pivotal trial of DURAVYU™ (vorolanib intravitreal insert) for wet age-related macular degeneration. In the full dataset, the primary endpoint of non-inferiority in best corrected visual acuity versus 2 mg on‑label aflibercept at weeks 52/56 was not achieved, which the company attributes to an asymmetric cohort of 9 of 211 DURAVYU patients who lost ≥15 letters from causes unrelated to wet AMD.
An ad hoc analysis excluding this 4% asymmetric cohort showed non‑inferiority for DURAVYU (nominal p=0.0096). Key secondary endpoints were favorable: a 42% reduction in treatment burden versus aflibercept (nominal p<0.0001), with DURAVYU patients receiving about two fewer injections on average through week 56; 76% of DURAVYU patients were supplement‑free to week 32 and 54% to week 56, and supplement‑free DURAVYU patients demonstrated non‑inferiority in BCVA to supplement‑free aflibercept (nominal p=0.0035). Anatomic control was strong, with only a 4‑micron difference in central subfield thickness at week 56 and a safety profile described as favorable with repeat dosing.
EyePoint expects topline data from the second wet AMD Phase 3 trial LUCIA in Q4 2026 and is planning a potential NDA submission in the first half of 2027, subject to LUCIA results. Two Phase 3 trials in diabetic macular edema, COMO and CAPRI, are fully enrolled, with topline data anticipated in Q4 2027.
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 7,000,000 shares of EyePoint, Inc. common stock, representing 8.35% of the class. All reported shares are held with shared voting and dispositive power; neither reporting person has sole voting or dispositive power.
The ownership percentage is calculated using 83,841,298 shares of common stock outstanding as of May 1, 2026, as referenced from EyePoint’s quarterly report for the period ended March 31, 2026. The shares are held by certain investment funds advised by Cormorant, and those funds have rights to dividends and sale proceeds, including one fund with rights over more than 5% of the shares.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 4,790,792 shares of EyePoint, Inc. common stock. This represents 5.71% of the company’s common stock, based on 83,841,298 shares outstanding as of May 1, 2026. The shares are held by Adage Capital Partners, L.P., with the Reporting Persons having shared voting and shared dispositive power over 4,790,792 shares and no sole voting or dispositive power.
EyePoint, Inc. reported second quarter 2026 results, with total net revenue of $0.5 million compared with $5.3 million a year earlier, primarily reflecting recognition of remaining deferred revenue from a 2023 YUTIQ license. Operating expenses rose to $97.9 million from $67.6 million, driven by pivotal DURAVYU Phase 3 trials in wet AMD and DME and commercial manufacturing scale-up.
The company recorded a net loss of $94.5 million, or ($1.09) per share, versus a net loss of $59.4 million, or ($0.85) per share in the prior-year quarter. Cash, cash equivalents, and marketable securities totaled $180 million as of June 30, 2026, down from $223 million as of March 31, 2026, and EyePoint states this is expected to fund operations into the fourth quarter of 2027.
Clinical execution remains a focus: pivotal Phase 3 wet AMD trials LUGANO and LUCIA (over 900 patients) are on track, with LUGANO topline data expected in August 2026 and LUCIA in the fourth quarter of 2026. Pivotal Phase 3 DME trials COMO and CAPRI have fully enrolled over 480 patients in five months, with topline data anticipated in the fourth quarter of 2027. EyePoint continues to position its investigational sustained-release TKI insert DURAVYU for wet AMD and DME within large retinal disease markets.
Vanguard Capital Management LLC reports a passive ownership stake in EyePoint Inc common stock on a Schedule 13G. Vanguard and certain affiliated entities beneficially own 4,223,415 shares, representing 5.03% of the outstanding common stock, with 4223415 shares subject to sole dispositive power and 593,163 shares subject to sole voting power.
The holdings include shares held by various Vanguard funds and managed accounts over which Vanguard entities exercise dispositive and/or voting power. No other single person’s interest in these securities exceeds 5% of the class. The filing is signed by an authorized signatory of Vanguard Capital Management.
EyePoint, Inc. completed enrollment in COMO and CAPRI, two pivotal global Phase 3 trials of DURAVYU™ for diabetic macular edema (DME). Over 480 patients were enrolled across both studies in about five months, ahead of schedule. The randomized, double-masked, on-label 2mg aflibercept controlled non-inferiority trials compare a 2.7mg DURAVYU intravitreal insert, re-dosed every six months, with on-label aflibercept using change in best corrected visual acuity at weeks 52 and 56 as the primary endpoint.
Secondary endpoints include safety, treatment burden, need for supplemental aflibercept injections, and anatomical outcomes by OCT. In May 2026 an independent Data Safety Monitoring Committee reviewed masked safety data from DURAVYU’s Phase 3 wet AMD and DME programs and recommended continuation without protocol modifications. DURAVYU has been studied in over 190 patients across four completed trials with no DURAVYU-related safety concerns reported. The wet AMD Phase 3 program (LUGANO and LUCIA) has randomized over 900 patients, with topline data anticipated beginning in August 2026, and topline 56-week data from the DME Phase 3 program expected in the fourth quarter of 2027.
BlackRock, Inc. filed Amendment No. 2 to a Schedule 13G reporting its beneficial ownership of common stock of EyePoint Pharmaceuticals, Inc.. BlackRock reports beneficial ownership of 6,430,477 shares of common stock, representing 7.7% of EyePoint’s outstanding common shares.
BlackRock has sole voting power over 6,290,331 shares and sole dispositive power over 6,430,477 shares, with no shared voting or dispositive power. The filing aggregates positions of certain BlackRock business units; other disaggregated units, if any, are excluded. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of EyePoint’s total outstanding common shares.